The glycoprotein hormones lutropin (LH) and thyrotropin and a limited number of additional glycoproteins bear carbohydrate structures terminating with the unique sequence SO 4 -4-GalNAcβ1,4GlcNAcβ that has been conserved in the glycoprotein hormones of all vertebrate species. Synthesis of these structures is mediated by a protein-specific β1,4GalNAc-transferase and a GalNAc-4-sulphotransferase (GalNAc-4-ST1). GalNAc-4-ST1 is a member of a family of sulphotransferases that includes HNK-1 sulphotransferase, chondroitin-4-sulphotransferases-1-3 and dermatan-4-sulphotransferase-1. With the exception of HNK-1-ST, these sulphotransferases add sulphate to the C-4 hydroxy group of either terminal or non-terminal β1,4-linked GalNAc. GalNAc-4-ST1 is most highly expressed in pituitary, cerebellum and other regions of the brain. The terminal GalNAcSO 4 on LH is recognized by the cysteine-rich domain of the mannose/GalNAc-4-SO 4 receptor located in hepatic endothelial cells. Each cysteine-rich domain binds a single terminal GalNAc-4-SO 4 , and the receptor must form non-covalently associated homodimers in order to simultaneously engage two GalNAc-4-SO 4 moieties on separate oligosaccharides with sufficient affinity to form stable complexes. The receptor mediates the clearance of LH from the blood. This clearance, in conjunction with the stimulated release of hormone from dense core granules in pituitary gonadotroph cells, is required to produce the episodic rise and fall in LH levels needed for optimal oestrogen production during the implantation of embryos in the uterus.
Glycoprotein hormone GalNAc-4-sulphotransferase
transfer of GalNAc by the GalNAc-transferase to terminal GlcNAc on N-linked oligosaccharides from 1 mM to 1-5 µM [14] [15] [16] . In the case of the glycoprotein hormone LH, three basic amino acids in the sequence Pro-Leu-Arg-Ser-Lys-Lys that is located N-terminal to an Asn glycosylation site on the α subunit are essential for recognition [17] . The basic residues are found within two turns of an α helix and allow the GalNAc-transferase to add GalNAc to multiple oligosaccharides chains.
The sequence of the recognition determinant and the Asn glycosylation sites are conserved in the sequence of the α subunits of all vertebrate species from fish to human, indicating that the glycoprotein hormones in all vertebrates have the potential to be modified with GalNAc-4-SO 4 . Furthermore, protein-specific β1,4-GalNAc-transferase and GalNAc-4-sulphotransferase activities with the same specificity as those found in mammals can be detected in extracts of pituitaries from fish, birds, reptiles and amphibians. Taken together with the fact that glycoprotein hormones from fish bear N-linked oligosaccharides terminating with GalNAc-4-SO 4 , this indicates that the unique sulphated structures originally described on bovine LH have been conserved throughout vertebrate evolution [18] . Conservation of these unique and complex carbohydrate structures, as with conservation of structural features encoded in the peptide sequence, indicates that these sulphated carbohydrate structures are important for the biological activity of LH and TSH in vivo.
Scheme 1 Synthesis of oligosaccharides terminating with GalNAc-4-SO 4
The N-linked oligosaccharides on glycoproteins containing a peptide recognition determinant are processed like those on glycoproteins that do not contain a determinant. Functional specificity of the sulphated oligosaccharide structure
The terminal GalNAc-4-SO 4 moiety on LH oligosaccharides determines the circulatory half-life of the hormone following its release into the blood [19] . We have demonstrated that the sulphated carbohydrate is recognized by the endocytic mannose/GalNAc-4-SO 4 receptor expressed by endothelial cells lining the sinusoids of the liver [20] [21] [22] . The mannose/GalNAc-4-SO 4 receptor is a multifunctional receptor that consists of an N-terminal cysteine-rich domain followed by a fibronectin type II repeat, eight carbohydrate recognition domains (CRDs), a transmembrane domain and a cytosolic domain [23, 24] . The cysteine-rich domain of the mannose/GalNAc-4-SO 4 receptor mediates binding of terminal GalNAc-4-SO 4 , whereas CRD4-CRD8, located adjacent to the transmembrane domain, bind saccharides terminating with mannose, GlcNAc or fucose [25] . The mannose/GalNAc-4-SO 4 receptor expressed by endothelial cells exists predominantly in the form of a dimer, whereas the same receptor when expressed by macrophages is monomeric [26] . The dimeric form of the mannose/GalNAc-4-SO 4 receptor binds LH by simultaneously engaging two terminal GalNAc-4-SO 4 moieties on separate oligosaccharides with a K d of 1.7 × 10 −7 M. The bound LH is rapidly internalized and transported to lysosomes, where it is degraded. Due to the large number of receptors (>600 000/hepatic endothelial cell) and the large number of endothelial cells in the liver (4 × 10 8 /rat liver), this receptor system has the capacity to bind a large percentage of the circulating LH in the blood and to clear LH at a constant rate. We have recently established the importance of LH clearance by the GalNAc-4-SO 4 receptor for oestrogen production and implantation [27] . Female mice deficient in one allele of the mannose/GalNAc-4-SO 4 receptor have a reduced rate of LH clearance and smaller litters than wild-type mice due to a reduced rate of implantation. Treatment with exogenous oestrogen restores the litter size to that of wild-type animals.
The GalNAc-4-sulphotransferase that adds sulphate to the terminal β1,4-linked GalNAc moiety on LH and other glycoproteins plays a key role in determining the rate and site of LH clearance in vivo. In the absence of sulphate, the terminal β1,4-linked GalNAc is recognized by the asialoglycoprotein receptor located in liver parenchymal cells (hepatocytes). LH bearing terminal GalNAc is removed from the blood by the asialoglycoprotein receptor 5-fold more rapidly than when it is recognized by the mannose/GalNAc-4-SO 4 receptor. Furthermore, more LH bearing oligosaccharides terminating with GalNAc is required to stimulate ovulation in vivo than native LH bearing terminal GalNAc-4-SO 4 [19] . Oligosaccharides terminating with GalNAcβ1,4GlcNAc can also be modified by addition of sialic acid to produce sialic acid-α2,6GalNAcβ1,4GlcNAc, or fucose to produce GalNAcβ1,4(Fucα1,3)GlcNAc (Scheme 1), unique structures that may be recognized by other carbohydratespecific receptor systems. As a result, the addition of sulphate, sialic acid and fucose to terminal GalNAcβ1,4GlcNAc sequences must also be regulated precisely to ensure that GalNAc-containing glycoproteins bind to the appropriate receptor.
Properties of the sulphotransferases that synthesize this unique oligosaccharide structure
We have cloned two GalNAc-4-sulphotransferases, GalNAc-4-ST1 [28] and GalNAc-4-ST2 [29] , that are capable of adding sulphate to N-linked oligosaccharides on LH and other glycoproteins. GalNAc-4-ST1 and GalNAc-4-ST2 [28] [29] [30] [31] [36, 37] . With the exception of HNK-1ST, which transfers sulphate to the C-3 hydroxy group of terminal β1,3-linked glucuronic acid, each of these sulphotransferases transfers sulphate to the C-4 hydroxy group of β1,4-linked GalNAc. However, the GalNAc must be internal in the repeating sequence [GalNAcβ1,4GlcAβ1,3] n of chondroitin or the repeating sequence [GalNAcβ1,4IdoUAα1,3] n of dermatan for transfer by C4ST-1, C4ST-2, C4ST-3 or dermatan-4-sulphotransferase-1 to occur. In contrast, GalNAc-4-ST1 and GalNAc-4-ST2 are active only against terminal GalNAcβ1,4GlcNAcβ. Like GalNAc-4-ST1 and GalNAc-4-ST2, HNK-1ST transfers sulphate to a sugar at the nonreducing terminus of a carbohydrate chain; however, transfer is to the C-3 hydroxy of glucuronic acid in the sequence GlcAβ1,3Galβ1,4GlcNAc, producing the HNK-1 epitope SO 4 -3-GlcAβ1,3Galβ1,4GlcNAc.
The structural features of this family of sulphotransferases and their saccharide substrates are shown schematically in Figure 1 . The seven members of this family of sulphotransferases display the highest percentage of identical amino acids within the regions that are proposed to bind the 5 -phosphosulphonate and the 3 -phosphate of 3 -phosphoadenosine 5 -phosphosulphonate, the high-energy sulphate donor [38, 39] . Regions III, IV and V (Figure 1) , which are located C-terminal to the 5 -phosphosulphonate and 3 -phosphate, are characteristic of this family of sulphotransferases, and also have a high percentage of identical amino acids; however, their functional significance remains to be elucidated.
We identified potential alternative splice forms lacking the transmembrane domain and a portion of the stem region for both GalNAc-4-ST1 [GalNAc-4-ST1(Met-119)] [28] and GalNAc-4-ST2 [GalNAc-4-ST2(Met-86)] [29] . When expressed in CHO cells, GalNAc-4-ST1(Met-119) and GalNAc-4-ST2(Met-86) were found exclusively in the medium. In contrast with GalNAc-4-ST1 and GalNAc-4-ST2, which did not transfer sulphate to either chondroitin or dermatan, the secreted forms of GalNAc-4-ST1(Met-119) and GalNAc-4-ST2(Met-86) were able to transfer sulphate to non-terminal GalNAc residues in chondroitin and dermatan. This suggests that sequences located Nterminal to the catalytic domains of GalNAc-4-ST1 and GalNAc-4-ST2 contribute to the specificity of the fulllength forms for terminal β1,4-linked GalNAc. The broader specificity of these truncated forms also emphasizes the close structural relationship between members of this family of sulphotransferases.
Sulphotransferase tissue distribution and its implications
Even though GalNAc-4-ST1 and GalNAc-4-ST2 have similar specificities and 46% identity in their amino acid sequences, they differ in their patterns of expression. GalNAc-4-ST2 is expressed highly in trachea, heart, liver and pancreas [29] , whereas GalNAc-4-ST1 is expressed in a number of different regions of the brain, with the highest levels of mature mRNA present in the pituitary, cerebellum and pons. GalNAc-4-ST1 mRNA was also detected in lymph nodes, and to a lesser extent in lung, spleen, adrenal gland, prostate, testis, atrium, mammmary gland and trachea [28] . While we have identified the corresponding gene in the mouse genome for GalNAc-4-ST1, we have not been able to identify the orthologue of GalNAc-4-ST2 in the mouse. Thus it appears that GalNAc-4-ST1 accounts for the addition of sulphate to the N-linked oligosaccharides on LH and TSH. The role of GalNAc-4-ST2 remains to be established.
Conclusions
The expression of GalNAc-4-ST1 mRNA in other regions of the brain is consistent with our earlier observation that both protein-specific β1,4-GalNAc-transferase and GalNAc-4-sulphotransferase activity could be detected in the cerebellum and cortex of the rat brain [40] . Glycoproteins bearing terminal GalNAc-4-SO 4 can be detected in the cerebellum, and are closely associated with the cell bodies and dendrites of Purkinje cells that extend into the molecular layer of the cerebellum [41] . We have determined that the multifunctional extracellular matrix glycoprotein tenascin-R bears N-linked structures that are modified with terminal GalNAc-4-SO 4 . Thus, as with LH and TSH in the pituitary, N-linked structures terminating with β1,4-linked GalNAc-4-SO 4 are confined to a small number of glycoproteins in the cerebellum. The amount of terminal GalNAc-4-SO 4 increases dramatically during the later stages of cerebellar development between postnatal days 14 and 21. This is the period of dendrite expansion into the molecular layer and synaptogenesis. Since tenascin-R is a multifunctional protein that interacts with a number of other matrix components, the addition of terminal GalNAc-4-SO 4 may serve to modulate specific interactions with these matrix components. Thus terminal GalNAc-4-SO 4 may fulfil a number of distinct biological functions in different settings.
The protein-specific addition of β1,4-linked GalNAc to N-linked oligosaccharides allows for the highly regulated synthesis of a family of unique carbohydrate structures that are confined to those proteins that contain the appropriate peptide recognition determinant. The addition of sulphate to β1,4-linked GalNAc produces unique structures terminating with GalNAc-4-SO 4 that appear to have different functions in different settings. It is likely that regulation of the synthesis of these structures will be complex, reflecting their multiple roles in vivo.
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